Transfected Stable Cell Lines
Reliable | High-Performance | Wide Rage
Precision reporter, kinase, immune receptor, biosimilar, Cas9, and knockout stable cell lines for diverse applications.
| Cat.No. | Product Name | Price |
|---|---|---|
| CSC-DC010018 | Panoply™ Human MYO15A Knockdown Stable Cell Line | Inquiry |
| CSC-SC010018 | Panoply™ Human MYO15A Over-expressing Stable Cell Line | Inquiry |
| Cat.No. | Product Name | Price |
|---|---|---|
| LV18973L | human MYO15A (NM_016239) lentivirus particles | Inquiry |
| Cat.No. | Product Name | Price |
|---|---|---|
| SHH212519 | shRNA set against Mouse Myo15(NM_010862.2) | Inquiry |
| SHH348080 | shRNA set against Mouse Myo15 (NM_182698.2) | Inquiry |
| SHH348088 | shRNA set against Human MYO15A (NM_016239.3) | Inquiry |
| Cat.No. | Product Name | Price |
|---|---|---|
| CDCR275714 | Mouse Myo15 ORF Clone(NM_182698.2) | Inquiry |
| CDFL008066 | Mouse Myo15 cDNA Clone(NM_182698.2) | Inquiry |
| MiUTR1H-06591 | MYO15A miRNA 3'UTR clone | Inquiry |
| MiUTR1M-07455 | MYO15 miRNA 3'UTR clone | Inquiry |
| MiUTR1M-07456 | MYO15 miRNA 3'UTR clone | Inquiry |
| CDCB182168 | Rabbit MYO15A ORF clone (XM_008250366.1) | Inquiry |
| CDCH391153 | Mouse Myo15 ORF clone(NM_010862.2) | Inquiry |
| CDCH391155 | Mouse Myo15 ORF clone(NM_001103171.1) | Inquiry |
| CDCH391156 | Human MYO15A ORF clone(NM_016239.3) | Inquiry |
The MYO15A gene is located at the DFNB3 locus. The researchers first discovered the DFNB3 locus for genome-wide screening of deaf patients from Indonesia. The study found that mouse shaker-2 syndrome is consistent with the localization of DFNB3 deafness in this conservative region, so it is speculated whether this mutation can be found in mice with a phenotype of shaker-2 syndrome and reveals the cause of the human DFNB3 deafness. Mutation of MYO15A gene is one of the causative causes of autosomal recessive non-combination syndrome.
The longest transcript encoded by the MYO15A gene includes 35390 amino acid residues (molecular weight 365 KDa), of which exon 2 encodes an extended N-terminus. This is followed by the motor domain of the head, including: ATP and myosin junction sites, type I and type II spirals, converter, subsequent spiral, SH3 helix, SH1/SH2 helix and a converter domain. The encoded myosin XVa can be divided into two subtypes based on the presence or absence of an N-terminal region encoded by exon 2 of the MYO15A gene in its head: myosin XVa-subtype 1 exists by exon 2 In the encoded N-terminal region, myosin XVa-subtype 2 has no N-terminal region.
Figure 1. The locations of MYO15A variants. (Chang, M. Y., et al. 2018)
MYO15A Mutation Related Mouse Model
Shaker2 (sh2) was first reported in 1928 as a progeny of rats exposed to X-ray ionizing radiation, showing poor response to sound, abnormal shaking and rotational behavior. Sh2 mouse Myo15a is located on chromosome 11 and is homologous to human DFNB3 at 17 pl 1.2. After injecting bacterial artificial chromosome BAC425p24 (140-kb t) (BACs) containing wild-type MYO15A into the fertilized eggs of homozygous mutant sh2 mice, the hearing power of sh2 mice recovered. The offspring of the breeding line carried BAC425p2 and the hearing was normal. It is through BAC that the hearing of sh2 mice can be restored, and MYO15A encoding unconventional myosin is finally identified.
Study on The Correlation between MYO15A Mutant Genotype and Hearing Phenotype
Studies have shown that the N'-end mutation encoded by exon 2 of MYO15A (p.G1112fsX1124) results in a light hearing phenotype with low frequency residual hearing. The study concluded that the hearing loss phenotype of MYO15A mutation patients is closely related to the region in which the gene mutation is located. Myosin XVa is divided into two subtypes, subtype 1 has an N-terminal region encoded by exon 2, and subtype 2 has no N-terminal region. Studies have shown that mutations in the N-terminal region result in abnormal myosin isoform 1 and the hearing phenotype is non-severe severe sensorineural hearing loss with residual hearing, such as reported MYO15A (p.Arg1112ValfsX1124), MYO15A (p .Tyr289X), MYO15A (p. Glu396Argfs*36) and MYO15A (p.Ser1176Valfs*14), etc. The hearing phenotypes that occur in the N-terminal region are low-frequency regions with residual hearing and sensorineural hearing loss.
Mutations in the N-terminal region of MYO15A exon 2 coding are associated with a non-severe hearing phenotype. The results of studies involving mutations in other regions and severe auditory phenotypes provide molecular genetic evidence for precision medical care in patients with MYO15A mutations. The degree of hearing loss can be predicted based on the different regions in which the MYO15A mutation is located. For mutations located in the N-terminal domain encoded by exon 2, low-frequency residual hearing needs to be considered, and low-frequency residual hearing is preserved as much as possible in cochlear implantation. Electroacoustic stimulation (EAS) was chosen as the best choice for hearing rehabilitation after surgery. MYO15A mutations encoding other domains require early consideration of cochlear implants and speech rehabilitation training.
References: